Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country is healthier and stronger."

As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, Medicare director Meena Seshamani, and FDA Center for Drug Evaluation and Research director Patrizia Cavazzoni have retired or intend to retire prior to Trump's inauguration on Jan. 20.

In a wide-ranging interview, Xavier Becerra, President Biden’s health secretary, defended his tenure and hinted that he might run for governor of California.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.

The talks around drugs including Novo Nordisk’s Wegovy, GSK’s Trelegy Ellipta, and Pfizer’s Xtandi will set Medicare prices that go into effect in 2027.

Medicare will negotiate drug prices for popular medications like Ozempic and Wegovy, aiming to save billions for taxpayers

The popular weight-loss drugs were added to Medicare’s list of prices negotiated directly between the government and drug manufacturers.